Coherus : FDA Delays Action On BLA For Toripalimab As Treatment For Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences Inc. (CHRS) said Sunday that they have not received an action letter from the U.S. Food and Drug Administration regarding the Biologics License Application (BLA) for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC) by the Prescription Drug User Fee Action (PDUFA) date of December 23, 2022.

According to the companies, the FDA previously communicated that an on-site inspection of Junshi Biosciences' manufacturing facility for toripalimab is required before the Agency can approve the application; however, the FDA was unable to conduct the inspection during the current review cycle due to the ongoing impact of COVID-19 related restrictions on travel in China. The BLA for toripalimab remains under review, and Junshi Biosciences and Coherus are engaged in ongoing discussions with the Agency about the pre-approval inspection plans.

Junshi Biosciences and Coherus said that they are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly as possible.

The FDA has granted priority review for the toripalimab BLA for use in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. Recurrent or metastatic NPC is an aggressive head and neck tumor which has no FDA-approved treatment options.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boeing and NASA announced further delay in the much expected launch of Starliner Crew Flight to the International Space Station following certain emerging issues with the capsule. Boeing has been developing its Starliner spacecraft after winning nearly $5 billion in contracts under NASA's Commercial Crew Program. Starliner's first crewed flight was earlier prepared for an April launch. Naperville, Illinois-based Chervon North America Inc. is recalling EGO Power+ Cordless Brushless Hedge Trimmers citing laceration hazard, the U.S. Consumer Product Safety Commission said. The recall involves EGO Power+ Model HT2410 Cordless Brushless Hedge Trimmers that were manufactured prior to March 30, 2019. About 85,000 units were sold in the United States and about 4,000 units were sold... Paterson, New Jersey - based E.N.A. Meat Packing Inc. is recalling around 39,947 pounds of frozen, raw lamb products that were imported without the benefit of import reinspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The products subject to recall include cartons weighing around 40-lb., containing raw frozen pieces of "Simunovic S.A. Frozen Bon
Follow RTT